The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo

Renal cell carcinoma (RCC) is a urologic malignant cancer and often diagnosed at an advanced stage, which results in high mortality. Targeted therapy may improve the quality of life and survival of patients who are not suitable for nephrectomy. Everolimus, an mTOR inhibitor, is currently used as seq...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yun, Wang, Jianfeng, Leng, Xuejiao, Huang, Jiwei, Xue, Wei, Zhang, Jin, Huang, Yiran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400548/
https://www.ncbi.nlm.nih.gov/pubmed/28212559
http://dx.doi.org/10.18632/oncotarget.15346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400548/
https://www.ncbi.nlm.nih.gov/pubmed/28212559
http://dx.doi.org/10.18632/oncotarget.15346

Ejemplares similares